Cancer treatment is often hindered by the lack of precise methods to identify which patients will respond to specific therapies, leading to ineffective treatments and unnecessary side effects. Traditional diagnostic methods may not fully capture the complex molecular characteristics of individual tumors, resulting in suboptimal treatment decisions.

OncXerna Therapeutics is developing an RNA-based biomarker platform designed to personalize cancer treatment by identifying unique tumor characteristics. This platform analyzes a patient's tumor RNA to predict their response to specific therapies, enabling clinicians to select the most effective treatment options. By understanding the molecular profile of each tumor, the platform aims to improve patient outcomes and reduce the use of ineffective treatments. The technology facilitates the development of tailored therapeutic strategies based on individual patient needs.

RNA-based biomarker analysis for comprehensive tumor profiling

Predictive algorithms to identify likely responders to specific cancer therapies

Identification of novel drug targets based on tumor-specific RNA signatures

Platform designed to integrate with existing clinical workflows

The primary target audience includes oncologists, pharmaceutical companies, and diagnostic laboratories seeking to improve cancer treatment outcomes through personalized medicine.